Island Pharmaceuticals Ltd has announced new data that will significantly streamline and reduce costs in its dengue fever clinical program. Following a successful Single Ascending Dose study for ISLA-101, which met all safety and dosing outcomes, new in silico dose modelling has confirmed the effectiveness of a single level, multi-day dose of ISLA-101. This approach achieves blood concentrations effective against the dengue virus, as demonstrated in pre-clinical studies, allowing the upcoming Phase 2 trial to proceed with a simplified and more informative design. CEO Dr. David Foster stated that the findings validate previous results and show that repeat dosing will enhance blood concentrations beyond effective levels.
